V C Nannapaneni

V C Nannapaneni


Having a rich experience of 42 years in the pharmaceutical industry, the Founder, Chairman & Managing Director of NATCO Pharma Limited (NATCO), Mr V C Nannapaneni is a self made personality who has escalated to greater heights through his sheer dedication and earnestness.

“Owing to Mr VCN’s dedicated efforts, NATCO has emerged as the largest domestic Oncology Company, providing affordable medicines to people”


Born in the village of Gollamudipadu, Guntur District, Andhra Pradesh, Mr V C Nannapaneni (VCN) evolved as a highly driven technocrat and entrepreneur with a strong will to contribute towards the development of the society. Besides holding Bachelors and Masters Degree in Pharmacy from Andhra University, Vishakapatnam, he also acquired a Masters degree in Pharmaceutical Administration from the Brooklyn College of Pharmacy, US. He has worked in the US for more than a decade in various Pharmaceutical companies.

Owing to his strong educational background in pharmaceuticals and rich international experience, Mr VCN established NATCO Fine Pharmaceuticals Pvt Ltd in 1981. During the subsequent years, he either established or acquired several other companies focused on drug manufacturing and research laboratories. It was in the year 1996 that the three group companies under Mr VCN were merged to form the present day NATCO which has generated revenues of INR 2,079 crore and has over 4500 employees.


Under the leadership and guidance of Mr VCN, NATCO has pioneered the introduction of many advanced pharmaceutical formulations. With the motto of “Making Specialty Medicines Accessible to All”, he drove the business ambitions of the firm, with specific inclination to the needs of the underprivileged. His quintessential motivation propelled the company to be the first to introduce sustained-release generic medicines in India, and its launch of anti-cancer drug, Imatinib Mesylate, in 2003, was a significant milestone in its journey into generic oncology segment.

Another bright feather in Mr VCN’s cap was the launch of the drug, Sorafenib, which was granted a compulsory license for anti-cancer drug by the Government of India in support of its mission to make medicines accessible & affordable to all in the country.

Owing to Mr VCN’s dedicated efforts, NATCO has emerged as the largest domestic Oncology Company, providing affordable medicines to the people and is also amongst the first companies to launch a highly effective generic medicine, Sofosbuvir under the brand Hepcinat, for curing Hepatitis C, in India. He made sure that with the affordable pricing of the company, therapy benefits could be availed by all the economic sections of the country, even in the semi- rural/rural areas and he also facilitated the delivery of free medicines to the poor and needy.


Under the leadership of Mr VCN, NATCO is committed to serving the society, and a result-oriented corporate social responsibility arm, NATCO Trust, has widened its coverage in line with the need of integrated development. He is efficiently spearheading the activities of
the Trust spread across three key areas: Education, Health and Livelihood.

Besides transforming at least 40 government schools by helping them to build toilets, renovate or furnish classrooms, and pay for Vidya volunteers, NATCO Trust, under his guidance, has also built two paediatric wards in Guntur Government Hospital with 100 beds to accommodate more children and provide timely healthcare for them. Mr VCN’s benevolent initiatives of donating ventilators and warmers for the hospital’s ICUs have been truly impactful and have saved thousands of lives.